Vanguard Group
HRTX icon

Vanguard Group’s Heron Therapeutics HRTX Stock Holding History

Vanguard Group’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$12.8M Buy
9,820,384
+1,360,600
+16% +$1.68M ﹤0.01% 2841
2025
Q3 		$10.7M Sell
8,459,784
-11,676
-0.1% -$18.5K ﹤0.01% 2952
2025
Q2 		$17.5M Buy
8,471,460
+245,875
+3% +$502K ﹤0.01% 2616
2025
Q1 		$18.1M Buy
8,225,585
+67,976
+0.8% +$132K ﹤0.01% 2554
2024
Q4 		$12.5M Sell
8,157,609
-562,567
-6% -$912K ﹤0.01% 2832
2024
Q3 		$17.4M Buy
8,720,176
+104,254
+1% +$249K ﹤0.01% 2657
2024
Q2 		$30.2M Buy
8,615,922
+501,206
+6% +$1.54M ﹤0.01% 2366
2024
Q1 		$22.5M Sell
8,114,716
-224,196
-3% -$564K ﹤0.01% 2544
2023
Q4 		$14.2M Buy
8,338,912
+169,632
+2% +$187K ﹤0.01% 2763
2023
Q3 		$8.41M Buy
8,169,280
+28,558
+0.4% +$40.6K ﹤0.01% 2974
2023
Q2 		$9.44M Sell
8,140,722
-289,896
-3% -$517K ﹤0.01% 2980
2023
Q1 		$12.7M Buy
8,430,618
+624,333
+8% +$1.56M ﹤0.01% 2807
2022
Q4 		$19.5M Sell
7,806,285
-946,556
-11% -$3.05M ﹤0.01% 2638
2022
Q3 		$36.9M Buy
8,752,841
+790,644
+10% +$3.09M ﹤0.01% 2325
2022
Q2 		$22.2M Sell
7,962,197
-1,972,491
-20% -$7.92M ﹤0.01% 2589
2022
Q1 		$56.8M Buy
9,934,688
+325,643
+3% +$2.38M ﹤0.01% 2242
2021
Q4 		$87.7M Buy
9,609,045
+108,753
+1% +$1.11M ﹤0.01% 2059
2021
Q3 		$102M Buy
9,500,292
+180,564
+2% +$2.2M ﹤0.01% 1971
2021
Q2 		$145M Buy
9,319,728
+828,512
+10% +$13.2M ﹤0.01% 1806
2021
Q1 		$138M Buy
8,491,216
+179,448
+2% +$3.2M ﹤0.01% 1783
2020
Q4 		$176M Buy
8,311,768
+310,669
+4% +$5.4M 0.01% 1534
2020
Q3 		$119M Sell
8,001,099
-28,439
-0.4% -$444K ﹤0.01% 1597
2020
Q2 		$118M Buy
8,029,538
+45,073
+0.6% +$741K ﹤0.01% 1587
2020
Q1 		$93.7M Buy
7,984,465
+127,899
+2% +$2.4M ﹤0.01% 1563
2019
Q4 		$185M Buy
7,856,566
+900,519
+13% +$19.9M 0.01% 1431
2019
Q3 		$129M Buy
6,956,047
+211,189
+3% +$3.89M ﹤0.01% 1583
2019
Q2 		$125M Buy
6,744,858
+330,351
+5% +$6.6M ﹤0.01% 1627
2019
Q1 		$157M Buy
6,414,507
+100,168
+2% +$2.62M 0.01% 1500
2018
Q4 		$164M Buy
6,314,339
+121,090
+2% +$3.33M 0.01% 1373
2018
Q3 		$196M Buy
6,193,249
+1,661,318
+37% +$61.9M 0.01% 1400
2018
Q2 		$176M Buy
4,531,931
+1,734,743
+62% +$55.2M 0.01% 1438
2018
Q1 		$77.2M Buy
2,797,188
+379,908
+16% +$8.62M ﹤0.01% 1854
2017
Q4 		$43.8M Buy
2,417,280
+347,787
+17% +$5.67M ﹤0.01% 2128
2017
Q3 		$33.4M Sell
2,069,493
-26,972
-1% -$423K ﹤0.01% 2252
2017
Q2 		$29M Buy
2,096,465
+221,362
+12% +$3.21M ﹤0.01% 2295
2017
Q1 		$28.1M Buy
1,875,103
+537,563
+40% +$7.44M ﹤0.01% 2284
2016
Q4 		$17.5M Buy
1,337,540
+26,560
+2% +$417K ﹤0.01% 2478
2016
Q3 		$22.6M Buy
1,310,980
+95,637
+8% +$1.77M ﹤0.01% 2314
2016
Q2 		$21.9M Buy
1,215,343
+58,039
+5% +$1.13M ﹤0.01% 2289
2016
Q1 		$22M Buy
1,157,304
+54,940
+5% +$1.08M ﹤0.01% 2257
2015
Q4 		$29.4M Buy
1,102,364
+24,726
+2% +$661K ﹤0.01% 2137
2015
Q3 		$26.3M Buy
1,077,638
+182,312
+20% +$6.08M ﹤0.01% 2167
2015
Q2 		$27.9M Buy
895,326
+226,015
+34% +$4.25M ﹤0.01% 2203
2015
Q1 		$9.74M Buy
669,311
+93,504
+16% +$1.05M ﹤0.01% 2659
2014
Q4 		$5.79M Buy
575,807
+11,274
+2% +$92K ﹤0.01% 2817
2014
Q3 		$4.7M Buy
564,533
+77,609
+16% +$723K ﹤0.01% 2866
2014
Q2 		$6M Buy
+486,924
New +$5.82M ﹤0.01% 2748

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group's HRTX Position: Q4 2025 in Review

Vanguard Group increased its Heron Therapeutics (HRTX) stake by 16% in Q4 2025, buying an estimated $1.68M and bringing the position to 9,820,384 shares worth $12.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2841.

Vanguard Group first reported a position in HRTX in Q2 2014 and has held it in 47 quarters since. The position peaked at $196M in Q3 2018. 170 funds tracked by Wall St. Rank hold HRTX as of Q4 2025.

  • Vanguard Group held 9,820,384 shares of Heron Therapeutics worth $12.8M as of Q4 2025.
  • Vanguard Group bought 1,360,600 Heron Therapeutics shares in Q4 2025, an estimated $1.68M.
  • Heron Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2841 holding.
  • Vanguard Group first reported a position in Heron Therapeutics in Q2 2014 and has held it in 47 quarters since.
  • Vanguard Group's Heron Therapeutics position peaked at $196M in Q3 2018.
  • 170 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.